Trautec
Trautec produces recombinant human collagen biomaterials via eukaryotic yeast fermentation, supplying B2B personal care, cosmetics, hair care, and medical customers in China and the United States.
- Company typePrivate
- Founded2015
- HeadquartersIrvine, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Trautec does
Trautec (Jiangsu Chuangjian Medical Technology Co., Ltd.) is a privately-held Chinese biotechnology company founded in 2015 that produces recombinant human collagen biomaterials via eukaryotic yeast fermentation. Its core technology synthesizes collagen with 100% amino acid sequence homology to natural human collagen while preserving the triple helix structure essential to biological function, directly addressing the zoonosis, contaminant, and allergenicity concerns associated with animal-derived collagen. Trautec operates a 100,000 square foot headquarters and manufacturing facility in Jiangsu, China, a 32,500 square foot CMA/CNAS-certified testing platform, and U.S. operations through Trautec Americas with offices in Irvine and Ontario, California. The intellectual property estate exceeds 60 authorized patents, including 3 PCT patents and 6 entries in the US PDB protein structure database, and the company has reached 30-ton scale fermentation production capacity.
The commercial product portfolio includes ReCol 3® (Type III recombinant human collagen for anti-aging, wrinkle relief, and skin barrier repair), ReCol 17® (Type XVII collagen for hair follicle and scalp health), MiniReCol3® and MiniReCol17® (small molecular weight variants for enhanced skin penetration), and Velastein™ (recombinant elastin for skin firmness), with SRHC Type I and Type II collagen listed as forthcoming. The company sells ingredients to B2B customers across personal care and cosmetics (primary), hair care, food and beverage, contract manufacturing, and medical and healthcare segments, with clinical applications in wound healing and regenerative medicine, including the world's first investigational clinical trial of recombinant collagen for skin burn treatment.
Trautec operates a B2B ingredient sales model with quote-based pricing and multi-year contracts, distributing through direct enterprise sales (phone and website sample requests), industry events such as NYSCC Suppliers Day, and ingredient marketplaces Knowde.com and UL Prospector. The company has raised approximately 400 million yuan across two rounds (Series A in July 2022 led by Shiseido Ziyue Fund; Series B in September 2023 co-led by L Catterton and CITIC Lyon Capital), reaching a 1 billion yuan post-money valuation. Strategic relationships include a medical beauty cooperation agreement with Shiseido, R&D collaborations with 30 Chinese provincial capitals, and clinical data partnerships with over 1,000 hospitals across China.
Trautec firmographics
Firmographics- Name
- Trautec
- Legal name
- Trautec Americas
- Website
- https://trautec.us
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Trautec produces recombinant human collagen biomaterials via eukaryotic yeast fermentation, supplying B2B personal care, cosmetics, hair care, and medical customers in China and the United States.
- Ownership category
- akta.pro rank
Trautec industry classification
Industry- Product category
- Cosmetic and medical biomaterial ingredients
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Proteins & Functional Nutrition Ingredients (Plant/Animal Proteins, Collagen, Amino Acids) (CRADAOAJ)
- akta.pro secondary industry
- Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)
Keywords
Where Trautec is headquartered
LocationHeadquarters
- HQ city
- Irvine
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Trautec business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- B2B Ingredient Sales: Trautec sells recombinant collagen ingredients (ReCol3, ReCol17, MiniReCol3, Velastein) to manufacturers in the personal care, cosmetics, and healthcare industries. Products available in powder, solution, and sponge formulations through distribution channels including Knowde.com and UL Prospector marketplace platforms.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B ingredient pricing - Quote-based |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Trautec product offering
Product offeringCore offering
Trautec produces recombinant human collagen biomaterials — including Type III, Type XVII, and small-molecular-weight variants — through proprietary eukaryotic yeast fermentation for use as ingredients in personal care, cosmetics, hair care, food & beverage, and medical device applications. Products are supplied in powder, solution, and sponge formulations to B2B customers, including manufacturers sourcing via Knowde.com and UL Prospector marketplaces and direct enterprise sales.
Product overview
Trautec offers a portfolio of recombinant human collagen products manufactured through eukaryotic yeast fermentation. The core product line includes ReCol 3® (Type III collagen for skin care and anti-aging), ReCol 17® (Type XVII collagen for hair follicle health and hair growth), and MiniReCol3® (small molecular weight variant for enhanced skin penetration). Additional products include Velastein™ (recombinant elastin for skin elasticity), SRHC Type I, SRHC Type II, and SRHC Type XVII collagen variants. All products are animal-free, sourced via yeast fermentation, and achieve 100% homology with human collagen for high biocompatibility.
Differentiator
Problem solved
Functional benefit
Brands
- ReCol 3®: Recombinant human Type III collagen for anti-aging, wrinkle relief, and skin barrier repair with 229 amino acids sequence.
- ReCol 17®
- MiniReCol3®
- Velastein™
Products and services
- ReCol 3® Type III recombinant human collagen derived from eukaryotic yeast featuring a 229 amino acid sequence. Designed for anti-aging, wrinkle relief, soothing efficacy, and skin barrier repair while promoting skin elasticity. For personal care and cosmetics manufacturers.
- ReCol 17® Type XVII recombinant human collagen for hair density enhancement and scalp health. Revitalizes hair follicle stem cells and supports keratinocyte differentiation to promote hair growth and delay scalp aging. For hair care product manufacturers.
- MiniReCol3® Small molecular weight (5 kDa) version of Type III collagen derived from eukaryotic yeast. Offers enhanced skin penetration efficacy with multiple active sites for rapid skin relief, anti-wrinkle, and firming benefits. For personal care formulators.
- MiniReCol17® Small molecular weight version of Type XVII collagen enabling transdermal absorption. Designed for anti-wrinkle and basement membrane repair applications.
- Velastein™ 6.01 kDa bioactive recombinant elastin for firmer, more elastic-looking skin. 100% homologous to human elastin, vegan and Halal certified, GMP manufactured. For personal care and skincare formulators.
Quantifiable outcome
- Top 35% ranking in EcoVadis 2023 Global Corporate Social Responsibility evaluation
- +2 more outcomes
Companies that use Trautec
Customer profileNamed customers2 records
Segments5 records
Ideal customer profiles4 records
Trautec technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Trautec partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- ShiseidocoreStrategic cooperation agreement focused on medical beauty. Following Shiseido Ziyue Fund investment, Trautec visited Shiseido Global Innovation Center in Yokohama, Japan to explore collaboration in functional skincare products and scalp care. Shiseido expressed appreciation for Trautec's recombinant collagen development.
Scale indicators14 records
Recent moves6 records
Expansion highlights6 records
Trautec competitors and assessment
Company assessmentDirect peers
- Modern Meadow: US biotech producing bioengineered, animal-free collagen and other proteins using fermentation, with a similar technology positioning targeting cosmetics and materials applications.
- Collplant Biotechnologies: Israel-based developer of recombinant human collagen (Type I) produced via transgenic plant-based expression, targeting medical devices, tissue engineering, and 3D bioprinting — same recombinant-collagen thesis but for medical applications.
- Geltor: US-based producer of animal-free recombinant proteins (including collagen and elastin) via fermentation for skincare, food, and personal care — directly comparable to Trautec's recombinant human collagen ingredients.
Broad incumbents
- Rousselot (Peptan): Global incumbent gelatin and collagen peptide manufacturer (Peptan brand) supplying beauty, nutrition, and food — established animal-derived collagen competitor Trautec is positioning against in the cosmetic-ingredient market.
- Symrise (Diana Food): Global flavors and nutrition/cosmetic ingredients major with a collagen peptide portfolio (e.g., Collperfect) for beauty-from-within and topical applications — broad incumbent in the collagen ingredients market.
- GELITA: One of the world's largest gelatin and collagen peptide producers, deeply embedded in nutraceutical, cosmetic, and food applications — broad incumbent on the animal-derived side of the market Trautec is targeting.
- Croda International: Major specialty ingredients supplier to the personal care industry with a broad actives portfolio including marine collagen and biomimetic peptides — incumbent Trautec would compete against for skincare brand specifications.
- Evonik (Health & Care / Collagen Solutions): Global specialty chemicals major with a peptide and collagen-based biomaterials portfolio (including collagen for medical devices); broad incumbent operating across cosmetics, nutrition, and medical end-markets.
- PB Leiner: Global supplier of gelatin and collagen peptides for food, nutrition, and personal care — established industrial-scale collagen ingredient competitor.
Regional players
- Jland Biotech: China-based recombinant collagen producer using yeast fermentation, offering competing Type III recombinant human collagen for cosmetics — most direct regional peer within the China market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Trautec social profiles
Digital presenceTrautec compliance and trust
Trust signalCompliance7 records
Trautec financial estimates
Financial estimateRevenue estimate
Valuation estimate
Trautec leadership team
Management profileNumber of profiles
Trautec funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Trautec M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Trautec
What does Trautec do?
Trautec produces recombinant human collagen biomaterials — including Type III, Type XVII, and small-molecular-weight variants — through proprietary eukaryotic yeast fermentation for use as ingredients in personal care, cosmetics, hair care, food & beverage, and medical device applications. Products are supplied in powder, solution, and sponge formulations to B2B customers, including manufacturers sourcing via Knowde.com and UL Prospector marketplaces and direct enterprise sales.
Is Trautec a public or private company?
Trautec is a private company. It is classified as venture growth investor backed and is currently operating.
When was Trautec founded?
Trautec was founded in 2015. It employs 251 to 500 people.
Where is Trautec based?
Trautec is headquartered in Irvine, United States, in the North America region.
How does Trautec make money?
One revenue line is on record: B2B Ingredient Sales.
Who are Trautec's main competitors?
Direct peers on record are Modern Meadow, Collplant Biotechnologies and Geltor. Broad incumbents are Rousselot (Peptan), Symrise (Diana Food), GELITA, Croda International, Evonik (Health & Care / Collagen Solutions) and PB Leiner. Jland Biotech is listed as a regional player.
Does Trautec have an API?
No public API is recorded for Trautec.
What industry is Trautec in?
Trautec's product category is Cosmetic and medical biomaterial ingredients. Its primary akta.pro industry code is CRADAOAJ, Proteins & Functional Nutrition Ingredients (Plant/Animal Proteins, Collagen, Amino Acids), with a secondary code of HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 325414 and its SIC code is 2836.